PIK3CA and breast cancer: Interestingly, while the selective p110α inhibitor alpelisib (BYL719) generated a positive response in PIK3CA mutant breast cancer, the additional loss of PTEN induced reactivation of p110β signalling and caused resistance to this targeted therapy [37,50,51].